NCT06784791View on ClinicalTrials.gov

Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2027

Conditions
Lung Cancer (NSCLC)
Interventions
DRUG

Amivantamab Intravenous

Stage 1: Pre-operative amivantamab monotherapy Stage 2: Pre-operative amivantamab treatment plus chemotherapy (carboplatin/pemetrexed)

DRUG

Carboplatin/Pemetrexed

Stage 2: Pre-operative amivantamab plus chemotherapy (carboplatin/pemetrexed)

Trial Locations (4)

3500

RECRUITING

Jessa Ziekenhuis, Department of Pneumology, Hasselt

45147

RECRUITING

West German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen

69126

RECRUITING

Thoraxklinik Heidelberg gGmbH, Studienzentrum Thoraxonkologie, Heidelberg

3015 GD

RECRUITING

Erasmus Universitair Medisch Centrum Rotterdam Department of Pulmonary Medicine, Rotterdam

All Listed Sponsors
lead

University Hospital, Essen

OTHER